Clinical Trial RTOG 0925
- Natural History of Postoperative Cognitive Function, Quality Of Life, and Seizure Control in Patients with Supratentorial Low-Risk Grade II Glioma
- Principal Investigator
- Priya Kumthekar
- Status: CLOSED
- Study Type: Observation, QOL
- Protocol No:.RTOG 0925
- The purpose of this study is to understand the effects of a brain tumor and surgery on the participant's cognitive function (thinking abilities, memory), quality of life, and seizures.
- This is a clinical trial, a type of research study for patients with low-grade (slow growing) glioma brain tumors. Doctors use standard regimens of therapy for treating brain tumors. Treatment decisions are generally based on changes in the size of the tumor over time. However it may possible to assess other things such as brain function (thinking abilities, memory, etc.) to determine if changes in treatment are needed. In this study, doctors are hoping to understand the changes in brain function with the goal that in the future more personalized treatment for low grade gliomas may be developed.
Some of the eligibility criteria include:
- Participants must have low grade glioma brain tumor.
- Participants must be 18 or older.
- Participants must begin the study within 84 days of their most recent cancer surgery.
- Description of Treatment
- Participation in this study involves the following tests and activities over a five year period: testing that measures aspects of the participant's thinking function at study entry and then at 7 additional time points; completion of 3 questionnaires at study entry and 5 additional time points; and completion of a record of seizures by the participant.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Priya Kumthekar
- A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
- A Phase 1 Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer
- A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined with Bevacizumab vs. Bevacizumab Monotherapy in Patients with Recurrent Glioblastoma
- A Phase II Trial of Bevacizumab in Patients with Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy
- A Phase 2, single arm, multi-center, open label trial Combining Optune with concurrent Bevacizumab in the setting of Recurrent or Progressive Meningioma
last updated: 28-Sep-16 03:29 AM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.